BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1256 related articles for article (PubMed ID: 10342079)

  • 21. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
    Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
    Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous use of mifepristone and misoprostol for early pregnancy termination.
    Li YT; Hsieh JC; Hou GQ; Chen TH; Chu YC; Lin TC; Kuan LC; Lin M; Tang HH; Kuo TC
    Taiwan J Obstet Gynecol; 2011 Mar; 50(1):11-4. PubMed ID: 21482367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486).
    el-Refaey H; Hinshaw K; Templeton A
    Hum Reprod; 1993 Oct; 8(10):1744-6. PubMed ID: 8300840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison or oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion.
    Mittal S; Agarwal S; Kumar S; Batra A
    Indian J Med Res; 2005 Aug; 122(2):132-6. PubMed ID: 16177470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early induction of abortion by a combination of oral mifepristone and misoprostol administered by the vaginal route.
    el-Refaey H; Templeton A
    Contraception; 1994 Feb; 49(2):111-4. PubMed ID: 8143450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral methotrexate and vaginal misoprostol for early abortion.
    Carbonell JL; Varela L; Velazco A; Cabezas E; Fernández C; Sánchez C
    Contraception; 1998 Feb; 57(2):83-8. PubMed ID: 9589833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medicamentous abortion with mifepristone and misoprostol in Serbia and Montenegro].
    Stojnić J; Ljubić A; Jeremić K; Radunović N; Tulić I; Bosković V; Dukanac J
    Vojnosanit Pregl; 2006 Jun; 63(6):558-63. PubMed ID: 16796021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of mifepristone and sublingual misoprostol for early medical abortion.
    Lin M; Li YT; Chen FM; Wu SF; Tsai CW; Chen TH; Kuo TC
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):321-4. PubMed ID: 17175490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion.
    Winikoff B; Sivin I; Coyaji KJ; Cabezas E; Xiao B; Gu S; Du MK; Krishna UR; Eschen A; Ellertson C
    Am J Obstet Gynecol; 1997 Feb; 176(2):431-7. PubMed ID: 9065194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mifepristone followed on the same day by vaginal misoprostol for early abortion.
    Pymar HC; Creinin MD; Schwartz JL
    Contraception; 2001 Aug; 64(2):87-92. PubMed ID: 11704084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of abortion in early pregnancy with mifepristone in conjunction with gemeprost.
    Somell C; Olund A
    Acta Obstet Gynecol Scand; 1993 Jan; 72(1):39-42. PubMed ID: 8382430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial.
    Creinin MD; Schwartz JL; Pymar HC; Fink W
    BJOG; 2001 May; 108(5):469-73. PubMed ID: 11368131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation.
    Løkeland M; Iversen OE; Engeland A; Økland I; Bjørge L
    Acta Obstet Gynecol Scand; 2014 Jul; 93(7):647-53. PubMed ID: 24766569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol.
    Tang OS; Gao PP; Cheng L; Lee S; Ho PC
    Contraception; 1998 Feb; 57(2):89-91. PubMed ID: 9589834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate and misoprostol used alone or in combination for early abortion.
    Ozeren M; Bilekli C; Aydemir V; Bozkaya H
    Contraception; 1999 Jun; 59(6):389-94. PubMed ID: 10518234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation.
    Tang OS; Xu J; Cheng L; Lee SW; Ho PC
    Hum Reprod; 2002 Jul; 17(7):1738-40. PubMed ID: 12093832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.
    Jain JK; Dutton C; Harwood B; Meckstroth KR; Mishell DR
    Hum Reprod; 2002 Jun; 17(6):1477-82. PubMed ID: 12042265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
    Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
    BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
    Middleton T; Schaff E; Fielding SL; Scahill M; Shannon C; Westheimer E; Wilkinson T; Winikoff B
    Contraception; 2005 Nov; 72(5):328-32. PubMed ID: 16246656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
    Chawdhary R; Rana A; Pradhan N
    J Obstet Gynaecol Res; 2009 Feb; 35(1):78-85. PubMed ID: 19215552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.